Andrew Reardon compensation by year
LIGAND PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $434,262 | $451,950 | $476,675 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $1,126,169 | $1,428,806 | $1,656,171 |
| Option awards | $596,045 | $1,142,820 | $1,332,345 |
| Non-equity incentive | $173,705 | $240,000 | $268,800 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $6,900 | $7,380 | $13,291 |
| Total | $2,337,081 | $3,270,956 | $3,747,282 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 21, 2026, accession 0000886163-26-000021, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 13,109 | $2,478,519 | — |
| RSU | 8,810 | $1,665,707 | — |
| RSU | 7,954 | $1,503,863 | — |
| RSU | 3,464 | $654,938 | — |
| Option | 22,784 | — | $115.26 |
| Option | 15,856 | — | $89.20 |
| Option | 4,489 | — | $75.09 |
| Option | 12,151 | — | $52.27 |
Per the Outstanding Equity Awards at Fiscal Year-End table in LIGAND PHARMACEUTICALS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments LIGAND PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $480,000 | $11,742,166 | $43,289 | $12,457,455 |
| Change in control, no termination | $0 | $0 | $0 | $0 |
| Involuntary termination without cause | $107,692 | $0 | $7,215 | $114,907 |
Per the Potential Payments Upon Termination or Change in Control table in LIGAND PHARMACEUTICALS INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
LIGAND PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Todd Davis | Chief Executive Officer | $11,472,095 |
| Octavio Espinoza | Chief Financial Officer | $4,382,148 |
| Andrew Reardon · this page | Chief Legal Officer and Secretary | $3,747,282 |
The full LIGAND PHARMACEUTICALS compensation record
free company briefThis page is one person within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order LIGAND PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LIGAND PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat